Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
Apellis Pharmaceuticals (APLS) and Sobi have commenced the Phase 3 VALIANT study for pegcetacoplan, targeting primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G). This study addresses a significant unmet need, as these rare conditions currently lack approved treatments. The trial involves approximately 90 patients aged 12 and older, with a primary endpoint of achieving at least a 50% reduction in urine protein-to-creatinine ratio after 26 weeks. The results of this study could have substantial implications for patient care and market potential.
- First patient dosed in Phase 3 VALIANT study for pegcetacoplan.
- Addresses significant unmet medical need in IC-MPGN and C3G with no approved treatments.
- Previous Phase 2 results support the efficacy of pegcetacoplan, enhancing future market prospects.
- None.
WALTHAM, Mass. and STOCKHOLM, Sweden, June 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced that the first patient has been dosed in the Phase 3 VALIANT study investigating pegcetacoplan, a targeted C3 therapy, in primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G), two rare and debilitating kidney diseases with similar underlying causes and no approved treatment.
“Individuals with IC-MPGN and C3G experience a high burden of disease due to the lack of approved treatments to slow or stop disease progression. These diseases often lead to kidney failure, requiring dialysis or a kidney transplant, imposing further substantial burdens,” said Kristen Hood, MSN, RN, executive director of research engagement at Nephcure Kidney International. “We are excited that Apellis and Sobi are advancing a Phase 3 study of pegcetacoplan in patients aged 12 and older, with primary IC-MPGN or C3G, including those with post-transplant recurrence.”
Uncontrolled activation of the complement cascade, a part of the body’s immune system, is believed to play a critical role in the progression of IC-MPGN and C3G where excessive accumulation of C3 breakdown products in the kidney causes inflammation and organ damage.1-4 It is estimated that 5,000 people in the United States and up to 8,000 in Europe are living with IC-MPGN or C3G,5 and approximately
“The positive Phase 2 results supported the advancement of pegcetacoplan to a confirmatory Phase 3 study in IC-MPGN and C3G,” said Jeffrey Eisele, Ph.D., chief development officer at Apellis. “There is a significant need for treatments for people living with these rare kidney diseases, and we believe pegcetacoplan, by targeting complement centrally at C3, may have the potential to protect kidney function and preserve patient quality of life.”
“Sobi and Apellis are the only companies actively pursuing a treatment for IC-MPGN,” said Anders Ullman, M.D., Ph.D., head of research and development and chief medical officer at Sobi. “We are pleased that the first patient has been dosed in this Phase 3 study for IC-MPGN and C3G, both of which represent an extremely high unmet medical need. We are committed to bringing a meaningful treatment to patients affected by these severe diseases.”
About the VALIANT Study
The VALIANT Phase 3 study (NCT05067127) is a randomized, placebo-controlled, double-blinded, multi-center study designed to evaluate pegcetacoplan efficacy and safety in approximately 90 patients who are 12 years of age and older with primary IC-MPGN or C3G. It is the only study to include both native kidney patients and patients who have recurrent disease after receiving a kidney transplant. Study participants will be randomized to receive 1080 mg of pegcetacoplan or placebo twice weekly for 26 weeks. Following this 26-week randomized controlled period, patients will proceed to a 26-week open-label phase in which all patients receive pegcetacoplan. The primary endpoint of the study is the proportion of study participants with a reduction from baseline in urine protein-to-creatinine ratio (uPCR) of at least
About Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and C3 Glomerulopathy (C3G)
IC-MPGN and C3G are rare, debilitating kidney diseases that are estimated to affect 5,000 people in the United States and up to 8,000 in Europe.5 There are no approved therapies for the diseases, and symptoms include blood in the urine, dark foamy urine due to the presence of protein, swelling, and high blood pressure.7 Approximately
About Pegcetacoplan in Rare Diseases
Pegcetacoplan is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, a part of the body’s immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is under investigation for several rare diseases across hematology, nephrology, and neurology. Pegcetacoplan is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the United States, Australia, and Saudi Arabia as EMPAVELI® and in the European Union and United Kingdom as Aspaveli®.
About the Apellis and Sobi Collaboration
Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, and Apellis has exclusive U.S. commercialization rights for systemic pegcetacoplan and retains worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy (GA).
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
About Sobi®
Sobi is a specialized international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of hematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East and Asia. In 2021, revenue amounted to SEK 15.5 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.
Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 4, 2022 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contacts:
Apellis
Media:
Lissa Pavluk
media@apellis.com
617.977.6764
Investors:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
Sobi
For details on how to contact the Sobi Investor Relations Team, click here. For Sobi Media contacts, click here.
____________
1. Smith RJH, et al. Nat Rev Nephrol. 2019;15:129-143.
2. Pickering MC, et al. Kidney Int. 2013;84:1079-1089.
3. Cook HT, Pickering MC. J Am Soc Nephrol. 2018;29:9-12.
4. Donadelli et al. Front Immunol. 2018;9:2329.
5. Data on file using literature consensus.
6. C3 glomerulopathy. National Institute of Health, Genetics Home Reference. https://ghr.nlm.nih.gov/condition/c3-glomerulopathy#resources. Accessed November 21, 2019.
7. Complement 3 Glomerulopathy (C3G). National Kidney Foundation Website. https://www.kidney.org/atoz/content/complement-3-glomerulopathy-c3g. Accessed November 21, 2019.
8. Noris M, Donadelli R, Remuzzi G. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatr Nephrol. 2019 Aug;34(8):1311-1323.
FAQ
What is the purpose of the VALIANT Study for APLS?
What are the key endpoints of the VALIANT Study?
How many patients are involved in the VALIANT Study?
What implications could the VALIANT Study results have for APLS?
What conditions does pegcetacoplan target in the VALIANT Study?
